PDF(Pubmed)
Abstract：
BACKGROUND: The aim of this study is to evaluate near and distance visual acuity (VA) and their correlation with the National Eye Institute Visual Function Questionnaire (NEI VFQ-25) outcomes in patients with diabetic macular edema (DME) and macular edema due to retinal vein occlusion (RVO) treated with aflibercept.
METHODS: In this prospective study, we included 87 eyes of patients diagnosed with DME (n = 61) and RVO (n = 26), who received aflibercept treatment and were followed until the 8th injection. Near VA was examined on the 1st, 2nd, 3rd, 4th, 6th, and 8th injection, and patients completed the NEI VFQ-25 on the 1st, 4th, and 8th aflibercept injection.
RESULTS: The mean near VA at baseline in all eyes was 0.89 ± 0.12 logMAR. With every administration, there was a statistically significant improvement; on the 4th (0.70 ± 0.19; p = 0.000) and the 8th application (0.60 ± 0.19; p = 0.000). At baseline, the mean NEI VFQ-25 total score was 71 ± 14%, and improved to 81 ± 13% (p = 0.000) on the 8th injection. The most significant score gain was recorded in the near VA subscale (+ 20 ± 14%, p = 0.000). There was no statistically significant difference between DME and RVO group in the questionnaire or near VA outcomes.
CONCLUSIONS: Aflibercept treatment resulted in a remarkable improvement of near vision by 4 lines of logMAR optotype after the 8th application. The near vision questionnaire subscale, initially scoring the lowest, exhibited the greatest gain during the treatment period. This underscores the importance of near vision and reading ability for patients with DME and RVO.
METHODS: In this prospective study, we included 87 eyes of patients diagnosed with DME (n = 61) and RVO (n = 26), who received aflibercept treatment and were followed until the 8th injection. Near VA was examined on the 1st, 2nd, 3rd, 4th, 6th, and 8th injection, and patients completed the NEI VFQ-25 on the 1st, 4th, and 8th aflibercept injection.
RESULTS: The mean near VA at baseline in all eyes was 0.89 ± 0.12 logMAR. With every administration, there was a statistically significant improvement; on the 4th (0.70 ± 0.19; p = 0.000) and the 8th application (0.60 ± 0.19; p = 0.000). At baseline, the mean NEI VFQ-25 total score was 71 ± 14%, and improved to 81 ± 13% (p = 0.000) on the 8th injection. The most significant score gain was recorded in the near VA subscale (+ 20 ± 14%, p = 0.000). There was no statistically significant difference between DME and RVO group in the questionnaire or near VA outcomes.
CONCLUSIONS: Aflibercept treatment resulted in a remarkable improvement of near vision by 4 lines of logMAR optotype after the 8th application. The near vision questionnaire subscale, initially scoring the lowest, exhibited the greatest gain during the treatment period. This underscores the importance of near vision and reading ability for patients with DME and RVO.
摘要：
背景：这项研究的目的是评估糖尿病性黄斑水肿（DME）和视网膜静脉阻塞（RVO）引起的黄斑水肿患者的近距和远距视力（VA）及其与美国国家眼科研究所视觉功能问卷（NEIVFQ-25）结果的相关性。
方法：在这项前瞻性研究中，我们纳入了诊断为DME（n=61）和RVO（n=26）的患者的87只眼，他接受了阿柏西普治疗，并一直随访到第8次注射。1号检查了VA附近,2nd,3rd,第四，6th,第8次注射,患者在1日完成了NEIVFQ-25，第四，和第8次阿柏西普注射液。
结果：所有眼睛基线时VA附近的平均值为0.89±0.12logMAR。每一届政府，有统计学上的显着改善；在第4次（0.70±0.19；p=0.000）和第8次应用（0.60±0.19；p=0.000）。在基线,平均NEIVFQ-25总分为71±14%，在第8次注射时提高到81±13%(p=0.000)。最显著的得分增加记录在近VA分量表中(+20±14%，p=0.000）。DME和RVO组在问卷或近VA结果上没有统计学上的显著差异。
结论：阿柏西普治疗在第8次应用后通过4行logMAR视模显著改善了近视力。近视力问卷分量表，最初得分最低，在治疗期间表现出最大的增益。这强调了DME和RVO患者近视力和阅读能力的重要性。
方法：在这项前瞻性研究中，我们纳入了诊断为DME（n=61）和RVO（n=26）的患者的87只眼，他接受了阿柏西普治疗，并一直随访到第8次注射。1号检查了VA附近,2nd,3rd,第四，6th,第8次注射,患者在1日完成了NEIVFQ-25，第四，和第8次阿柏西普注射液。
结果：所有眼睛基线时VA附近的平均值为0.89±0.12logMAR。每一届政府，有统计学上的显着改善；在第4次（0.70±0.19；p=0.000）和第8次应用（0.60±0.19；p=0.000）。在基线,平均NEIVFQ-25总分为71±14%，在第8次注射时提高到81±13%(p=0.000)。最显著的得分增加记录在近VA分量表中(+20±14%，p=0.000）。DME和RVO组在问卷或近VA结果上没有统计学上的显著差异。
结论：阿柏西普治疗在第8次应用后通过4行logMAR视模显著改善了近视力。近视力问卷分量表，最初得分最低，在治疗期间表现出最大的增益。这强调了DME和RVO患者近视力和阅读能力的重要性。
